ТТП

Применение ритуксимаба у гематологических больных с ВИЧ-инфекцией

МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА И ВИЧ-ИНФЕКЦИЯ , , , ,

А.В. Пивник

Медицинский центр «Генотехнология», Москва, Российская Федерация

РЕФЕРАТ

Ритуксимаб (Мабтера) – один из мощных лекарственных препаратов, избирательно действующий на В-клетки. В случаях аутоиммунных заболеваний,  препарат супрессирует поликлональный ответ антителами на собственные антигены. При лимфатических опухолях он избирательно действует на опухолевые В-клетки. Ритуксимаб широко используется для лечения ряда аутоиммунных заболеваний и лимфатических опухолей. Показано успешное применение препарата у больных иммунной тромбоцитопенической пурпурой (ИТП), тромботической тромбоцитопенической пурпурой Мошковица (ТТП), аутоиммунной гемолитической анемией (АИГА), ревматоидным артритом (РА), системной красной волчанкой (СКВ), болезнью Крона и другими заболеваниями. В обзоре приведены описания клинических наблюдений у больных с перечисленными заболеваниями. Все пациенты инфицированы ВИЧ на разных стадиях течения заболевания. Показана эффективность применения препарата и умеренная его токсичность. Основные показатели ВИЧ-инфекции (уровень CD4 и вирусная нагрузка) не зависели от применения препарата. В целом, показана положительная оценка использования ритуксимаба у ВИЧ-инфицированных пациетов.

Ключевые слова: ритуксимаб и ВИЧ-инфекция, ИТП, АИГА, ТТП, лимфомы у ВИЧ-инфицированных больных.

Читать статью в PDFpdficon

ЛИТЕРАТУРА

  1. Ермак Т.Н., Кравченко А.В., Шахгильдян В.И. Анализ причин летальных исходов больных ВИЧ-инфекцией в Российской Федерации. Инфек. бол. 2010; 3: 19–20. [Ermak T.N., Kravchenko A.V., Shakhgil’dyan V.I. Analiz prichin letal’nykh iskhodov bol’nykh VICh-infektsiei v Rossiiskoi Federatsii (Analysis of causes of death in patients with HIV infection in the Russian Federation). Infek. bol. 2010; 3: 19–20.]
  2. Покровский В.В., Ермак Т.Н., Беляева В.В., Юрин О.Г. ВИЧ-инфекция. Клиника, диагностика, лечение. Под ред. В.В. Покровского, 2-е изд. М.: ГЭОТАР-Медиа, 2003. [Pokrovskii V.V., Ermak T.N., Belyaeva V.V., Yurin O.G. VICh-infektsiya. Klinika, diagnostika, lechenie. Pod red. V. Pokrovskogo, 2-e izd. (HIV infection. Clinical presentation, diagnostics, treatment. Ed. by V.V. Pokrovskii, 2nd ed.). M.: GEOTAR-Media, 2003.]
  3. Покровский В.В. Заболеваемость ВИЧ-инфекцией в Федеральных округах России на конец 2008 г. Эпидемиол. и инфек. бол. 2009; 6: 15–7. [Pokrovskii V.V. Zabolevaemost’ VICh-infektsiei v Federal’nykh okrugakh Rossii na konets 2008 g. (HIV infection incidence in the Federal regions of Russia by the end of 2008). i infek. bol. 2009; 6: 15–7.]
  4. http://data unaids.Org/publication/RC-publication/RC-pub06/jc1038-changingepidemic_en.pdf. The changing HIV/AIDS epidemic in Europe and Central Asia. 2004.
  5. Покровский В.В. Распределение ВИЧ-инфицированных по основным путям заражения на территории г. Москвы за период с 2000 по 2008 г. Эпидемиол. и инфек. бол. 2009; 8: 12–4. [Pokrovskii V.V. Raspredelenie VICh-infitsirovannykh po osnovnym putyam zarazheniya na territorii g. Moskvy za period s 2000 po 2008 g. (Distribution of HIV infection patients according to main modes of HIV transmission within the area of Moscow from 2000 to 2008). Epidemiol. i infek. bol. 2009; 8: 12–4.]
  6. Тишкевич О.А., Шахгильдян В.И., Пархоменко Ю.Г. Структура летальных исходов и патологчиеская анатомия у больных ВИЧ-инфекцией в Москве. Эпидемиол. и инфек. бол. 2004; 4: 42–6. [Tishkevich O.A., Shakhgil’dyan V.I., Parkhomenko Yu.G. Struktura letal’nykh iskhodov i patologchieskaya anatomiya u bol’nykh VICh-infektsiei v Moskve (Mortality pattern and pathologic anatomy in HIV infection patients). Epidemiol. i infek. bol. 2004; 4: 42–6.]
  7. Barcellini W., Zaja F., Zaninoni et al. Low-Dose Rituximab In Idiopathic Autoimmune Hemolytic Anemia: Biological Studies. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 3206.
  8. Ratner L. HIV-1 associated thrombocytopenia. In: Aids Clinical Treatment Group Meeting, Washington, July 1988, pp 13–15.
  9. Schneider P.A., Abrams D.I., Rayner A.A., Hohn D.C. Immunodeficiency associated thrombocytopenic purpura (IDTP). Surg. 1987; 122: 1175–8.
  10. Giagounidis A.A., Anhuf J., Schneider P. et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur. J. Haematol. 2002; 69: 95–100.
  11. Cooper N., Stasi R., Cunningham-Rundles S. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 2004; 125: 232–9.
  12. Ahmad H.N., Ball C., Height S.E., Rees D.C. Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. Br. J. Haematol. 2004; 127: 607–8.
  13. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952–7.
  14. Волкова М.А., Бялик Т.Е. Ритуксимаб в терапии аутоиммунных осложнений при хроническом лимфолейкозе. Гематол. и трансфузиол. 2006; 3: 11–7. [Volkova M.A., Byalik T.E. Rituksimab v terapii autoimmunnykh oslozhnenii pri khronicheskom limfoleikoze (Rituximab treatment of autoimmune complications in chronic lymphocytic leukemia). Gematol. i transfuziol. 2006; 3: 11–7.]
  15. Филатов Л.Б., Томилов А.Ф., Алексеева Т.А. Гемолитическая анемия, вызванная фрагментацией эритроцитов. Клин. онкогематол. 2011; 4(4): 346–55. [Filatov L.B., Tomilov A.F., Alekseeva T.A. Gemoliticheskaya anemiya, vyzvannaya fragmentatsiei eritrotsitov (Hemolytic anemia induced by erythrocyte fragmentation). Klin. onkogematol. 2011; 4(4): 346–55.]
  16. Ross C.L., Hunt B.J., Wyncoll D. et al. HIV, thrombotic thrombocytopaenic purpura and rituximab in a violent noncompliant patient. Blood Coagul. Fibrinol. 2009; 20: 157–60.
  17. Evans M.W., Vaughan L.B., Giffi V.S. et al. Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated with Human Immunodeficiency Virus Failing Extensive Treatment with Plasma Exchange: A Report of Two Cases. AIDS Patient Care STDs 2010; 24(6): 349–52.
  18. Goedert J.J., Cote T.R., Virgo P. et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833–
  19. Clarke C.A., Glaser S.L. Epidemiological trends in HIV-associated lymphomas. Curr. Opin. Oncol. 2001; 13: 354–9.
  20. Little R.F. AIDS-related non-Hodgkin’s lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy. Lymphoma 2003; 44(3): 63–8.
  21. Gerard L., Galicier L., Maillard A. et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. AIDS 2002; 30: 478–84.
  22. Glaser S.L., Clarke C.A., Gulley M.L. et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Great San Francisco Bay Area, 1988–1998. Cancer 2003; 98(2): 300–9.
  23. Powles T., Imami N., Nelson M. et al. Effects of combination chemotherapy and HAART on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531–620.
  24. Пивник А.В., Пархоменко Ю.Г., Криволапов Ю.А. и др. Соматические проблемы ВИЧ-медицины: СПИД-ассоциированные лимфомы. Онкогематология 2007; 3: 27–37. [Pivnik A.V., Parkhomenko Yu.G., Krivolapov Yu.A. i dr. Somaticheskie problemy VICh-meditsiny: SPID-assotsiirovannye limfomy (Somatic problems of HIV medicine: AIDS-associated lymphomas). Onkogematologiya 2007; 3: 27–37.]
  25. Ribera J.M., Oriol A., Morgades M. et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br. J. Haematol. 2008; 140(4): 411–9.
  26. Sparano J.A., Lee J.Y., Kaplan L.D. et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115(15): 3008–16.
  27. Dunleavy K., Little R.F., Pittaluga S. et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010; 115(15): 3017–24.
  28. Gang A.O., Strom C., Pedersen M. et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-29. A population-based investigation from the Danish Lymphoma Group. Ann. Oncol. 2012; 23: 147–53.
  29. Mazloom A., Fowler N., Medeiros L.J. et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Lymphoma 2010; 51(7): 1217–24.
  30. Simonelli C., Zanussi S., Cinelli R. et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Infect. Dis. 2003; 37: 820–7.
  31. Powles T., Imami N., Nelson M. et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531–6.
  32. Пивник А.В., Серегин Н.В., Туманова М.В. и др. Агрессивные лимфомы полости рта и придаточных пазух носа у больных СПИДом. Описание 9случаев. Клин. онкогематол. 2009; 2(4): 349–57. [Pivnik A.V., Seregin N.V., Tumanova M.V. i dr. Agressivnye limfomy polosti rta i pridatochnykh pazukh nosa u bol’nykh SPIDom. Opisanie 9 sluchaev (Aggressive lymphomas of oral cavity and accessory nasal sinuses in AIDS patients: 9 cases report). Klin. onkogematol. 2009; 2(4): 349–57.]
  33. van Aalderen M.C., Brinkman K., van den Berk G.E., Terpstra W.E. Vinblastine, rituximab and HAART, treatment of an HIV-positive patient with multicentric Castleman’s disease. J. Med. 2010; 68(2): 87–90.
  34. Hoffmann C., Schmid H., Muller M. et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011; 118: 3499–503.
  35. Johns R.H., Doyle T., Lipman M.C. et al. Successful treatment of HIV-associated multicentric Castleman’s disease and multiple organ failure with rituximab and supportive care: a case report. J. Med. Case Rep. 2010; 4: 32.
  36. Bower M., Powles T., Williams S. et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Intern. Med. 2007; 147(12): 836–9.
  37. Gerard L., Berezne A., Galicier L. et al. Prospective study of rituximab in chemotherapy dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J. Clin. Oncol. 2007; 25(22): 3350–6.
  38. Bower M., Veraitch O., Szydlo R. et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009; 113(19): 4521–4.
  39. Marcelin A.-G., Aaron L., Mateus C. et al. Rituximab therapy for HIV-associated Castleman disease: long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2003; 102(8): 2786–8.
  40. Neuville S., Agbalika F., Rabian C. et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. J. Hematol. 2005; 79(4): 337–9.
  41. Buchler T., Dubash S., Lee V. et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman’s disease with multiorgan failure: report of two cases. AIDS 2008; 22(13): 1685–7.
  42. Rodriguez J., Gutierrez A., Palacios A. et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk. Lymphoma 2007; 48(11): 2172–8.
  43. Spurgeon S.E., Pindyck T., Okada C. et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk. Lymphoma 2011; 52(8): 1488–94.
  44. Sachanas S., Pangalis G.A., Vassilakopoulos T.P. et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk. Lymphoma 2011; 52(3): 387–93.
  45. Barnes J.A., LaCasce A.S., Feng Y. et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann. Oncol. 2011; 22: 1859–64.
  46. Crosswell H.E., Bergsagel D.J., Yost R., Lew G. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatr. Blood Cancer 2008; 50(4): 883–5.
  47. Rodrigo J.A., Hicks L.K., Cheung M.C. et al. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Advances in Hematology, 2012, Article ID 735392.
  48. Dunleavy K., Wilson W.H. How I treat HIV-associated lymphoma. Blood 2012; 119: 3245–55.
  49. Pei S.N., Chen C.H., Lee C.M. et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Hematol. 2010; 89: 255–62.
  50. Matsue K., Kimura S., Takanashi Y. et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116(20): 4769–76.
  51. Boyle S.F., Reid E.G. Viral reactivation and clinical hepatitis in patients with hepatitis C who receive rituximab as part of chemotherapy for treatment of lymphoma: A case series. ASCO Meeting Abstracts 2010; 28: e18559.
  52. Carson K.R., Focosi D., Major E.O. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009; 10(8): 816–24.
  53. Carson K.R., Evens A.M., Richey E.A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 14; 113(20): 4834–40.